VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO WCGIC 2020 | Regorafenib + nivolumab in MMR proficient advanced CRC

Richard D. Kim
ESMO WCGIC 2020
Colorectal Cancer Gastrointestinal Cancer Antibodies Nivolumab Regorafenib
Immuno-Oncology

Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses results of a Phase I/IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Richard D. Kim

2:47
Immunotherapy plus TKIs for the treatment of CRC
Richard D. Kim • 27 Jan 2022
3:17
TOPAZ-1: the addition of durvalumab to chemotherpay for the treatment of BTC in the 1st-line setting
Richard D. Kim • 27 Jan 2022
2:10
Anti-EGFR therapy for RAS wild-type left-sided colorectal cancer
Richard D. Kim • 6 Jun 2022
2:40
Biomarker analysis of nivolumab in patients with advanced refractory biliary tract cancer
Richard D. Kim • 26 Jan 2023

Related Videos

1:44
EuropaColon survey of the unmet needs of metastatic colorectal cancer patients
Geoffrey Henning
3:24
COVID-19 & the management of cancer patients
Alberto F. Sobrero
1:20
A promising future for drug development in gastrointestinal cancer
Hani Babiker
2:31
Treatment landscape for HCC
Arndt Vogel
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals